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The heart is a perfect machine whose
mass is mainly composed of cardiomy-
ocytes, but also fibroblasts, endothelial,
smooth muscle, nervous, and immune
cells are represented. One thousand mil-
lion cardiomyocytes are estimated to be
lost after myocardial infarction, their loss
being responsible for the impairment in
heart contractile function (Laflamme and
Murry, 2005).
The potential success of cardiac cell
therapy relies almost completely on the
ability of the implanted cells to differenti-
ate toward mature cardiomyocytes. These
cells must be able to reinforce the pumping
activity of the injured heart in the absence
of life-threatening arrhythmias due to
electrophysiological incompatibility.
These conditions can only be met if the
newly formed cardiomyocytes can inte-
grate electromechanically with the host
tissue while getting appropriate vascu-
larization from host- or donor-derived
vessels.
Together with the regeneration of the
contractile component of the heart, atten-
tion must be paid to the search for
novel methods to deliver appropriate vas-
cularization to the ischemic areas and
to the preservation of structures control-
ling the efficiency of blood pumping to
the organism: the heart valves. Although
fetal, neonatal, and adult cardiomyocytes
have been tested for their actual ability
to engraft diseased heart and improve its
function (Dowell et al., 2003), most of the
hopes in cardiac tissue regeneration relies
on the possibility to use pluripotent and
adult stem cells in targeted tissue engineer-
ing applications.
In this respect, the set-up of protocols
to obtain reprogrammed pluripotent stem
cells (Takahashi and Yamanaka, 2006), a
discovery awarded with the Nobel Prize in
Physiology orMedicine in 2012, represents
the demonstration that such advances in
knowledge and technology will eventually
lead to novel approaches to the treatment
of incurable diseases.
Unfortunately, notwithstanding a
decade of intense investments, the results
in terms of knowledge transferred to the
clinical practice are very limited.
The present issue addresses the topic
of cardiac tissue regeneration from the
viewpoint of stem cell biologists and tis-
sue engineers, seeking for the most appro-
priate source of cells to replace dead
myocardium, improve the organ struc-
ture and function, as well as exploring
the most suitable delivery system for such
cells.
In the last couple of years a number of
papers have been published on the ability
of biomaterials and bio-constructs to drive
the differentiation of stem cells for car-
diac tissue engineering applications. Most
of these studies used mesenchymal stem
cells (MSCs) from bone marrow, adipose
tissue or induced pluripotent stem cells
(iPSCs). On the other hand, the contribu-
tion of cells derived from the heart tissues
is here considered of outmost importance
since these cells are believed to retain the
potential to become highly differentiated
cardiomyocytes.
LOOKING FOR SOURCES OF
CONTRACTILE CELLS
Studies on the differentiation of embry-
onic cells into cardiomyocytes started in
1989 (Rudnicki et al., 1989). From that
time, many candidates have been taken
into consideration to substitute dead con-
tractile cells, as myoblasts, hematopoietic
lineages, and cardiac side populations.
While skeletal myoblasts can gener-
ate contractile cells that cannot cou-
ple electromechanically with the host
myocardium (Forte et al., 2013), the other
two stem cell subsets, hematopoietic stem
cells (HSCs) and MSCs, are now univer-
sally recognized to retain no capacity to
acquire the contractile phenotype (Balsam
et al., 2004; Murry et al., 2004; Gnecchi
et al., 2005; Siegel et al., 2012).
In the case of HSCs, after contrasting
papers were published by the group of
Piero Anversa and Charles E. Murry, the
compelling conclusion that this bone mar-
row subset is not suitable for contractile
cell regeneration was agreed (Orlic et al.,
2001; Balsam et al., 2004; Murry et al.,
2004).
The resistance of the other bone
marrow-derived stem cell subset (bone
marrow MSCs) as candidate to produce
new cardiomyocytes has been even longer:
after a seminal paper published by the
group of Keiichi Fukuda in 1999 (Makino
et al., 1999) it took more than 10 years
to clarify that bone marrow mesenchymal
progenitors have no cardiogenic potential.
A convincing investigation by Siegel
and collaborators finally clarified that
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human MSCs are indeed able to acquire
specific cardiomyocyte markers in vitro,
while failing to show contractile func-
tional features. When implanted in an in
vivo model of rodent myocardial infarc-
tion, MSCs do not completely differentiate
into functional cardiomyocytes, proving
that BM-derived MSCs may not be used in
cardiac regeneration (Siegel et al., 2012).
Additionally, the work of the group of
Massimiliano Gnecchi recently explained
the positive outcome of many pre-clinical
and clinical trials entailing MSC adminis-
tration, by showing that the predominant
effect of implanted MSCs in the heart con-
sists in the secretion of anti-apoptotic sig-
nals for the resident cells (Gnecchi et al.,
2005).
The same mechanism has been recalled
to explain the modest but positive results
obtained by vessel-associated mesan-
gioblast implantation in infarcted heart
(Galli et al., 2005) and may be respon-
sible of the positive outcome of the
implantation of epicardially delivered adi-
pose tissue-derived stromal cell (ADSC)
sheets in a mouse model of dilated
cardiomyopathy (Hamdi et al., 2013).
Other sources of mesenchymal pro-
genitors are still credited of cardiogenic
potential: the process of adipocyte ded-
ifferentiation to produce mesenchymal
progenitors has been known for some
years, while only recently evidence that
dedifferentiated adipocytes and adipose-
derived mesenchymal cells can sponta-
neously acquire the contractile phenotype
in vitro and help tissue healing in vivo was
given (Jumabay et al., 2009). Interestingly,
the use of this cell source for car-
diac regeneration therapy would pose no
availability issue, nor any immunological
concern.
The choice of the cell and the con-
struct to implant is of outmost impor-
tance. With the usefulness of MSCs as an
easy source of cells for autologous implan-
tation being questioned, the search for the
best candidate as contractile cell substitute
is still open. The use of cardiac resident
progenitor cells—firstly being identified
by Quaini et al. (2002) based on c-Kit+
expression and already being tested in a
clinical trial (Bolli et al., 2011)—appears to
be a promising alternative for cardiac tis-
sue engineering. Nonetheless, compelling
evidence of their efficacy in vivo still needs
to be provided by independent research
groups.
No matter the route of delivery of
cells to the cardiac tissue and the cell
source, small but significant improve-
ments in terms of cardiac function have
been repeatedly reported mainly through
a paracrine effect (Mirotsou et al., 2011),
while the goal of regenerating massive por-
tions of cardiac tissue still remains elusive.
CARDIAC PROTO-TISSUES: TRYING TO
REPRODUCE THE COMPLEXITY OF THE
MYOCARDIUM
The complexity of the myocardium resides
in the number of cell types repre-
sented in it and in its highly hierarchical
organization.
The ideal cardiac-specific scaffold
would comply with cardiac muscle archi-
tecture, be deformable enough to sustain
cardiac contraction, while being colonized
by host vasculature and resorbed/degraded
in due time. The biomaterials and scaf-
folds so far proposed for cardiac tissue
engineering can be grouped into three
categories: (1) scaffolds mimicking extra-
cellular matrix (ECM) structure and/or
the elasto-mechanical properties of the
myocardium, (2) in vitro engineered
cardiac patches, (3) three-dimensional
(3D) scaffolds reproducing myocardial
structural properties.
Culturing cells in three dimensions or
on substrates displaying the mechanical
properties of the myocardium has been
deemed sufficient to prompt cardiac com-
mitment but not complete maturation per
se (Engler et al., 2006; Di Felice et al.,
2013).
The attempts at designing scaffolds
mimicking ECM structure and replicat-
ing the in vivo structural and mechanical
features of the ECM, in order to provide
stem cells with meaningful cues and com-
ply with the architecture of the host tissue
are far from being successful.
In an attempt to reproduce cardiac
ECM stiffness, polyurethane acrylate
(PUA) mold was recently used to pattern
polyurethane (PU) and poly(lactide-
co-glycolide) (PLGA) hydrogels via
UV-assisted or solvent-mediated capillary
force lithography (CFL) (MacAdangdang
et al., 2014).
Alternatively, the combination of cell
electrospraying and electrospinning to
generate a solution of hydrogel and
polyurethane blend was also proposed (Xu
et al., 2014).
A natural approach to the issue of
reproducing the ECM mechanics and
topography was proposed by adopting
human pericardium membranes to cre-
ate 3D microporous scaffolds (Rajabi-
Zeleti et al., 2014), or by using decellu-
larized human myocardium as a bioma-
terial for cardiac tissue regeneration and
engineering (Oberwallner et al., 2014).
Finally, hybrid biomimetic membranes
were developed for cardiac tissue regen-
eration by binding the epitope sequences
of laminin and fibronectin to poly(glycerol
sebacate) (PGS) films (Rai et al., 2013).
The same polymer has been successfully
manufactured to obtain scaffolds display-
ing the anisotropic elasticity typical of the
myocardium and promoting neonatal car-
diomyocyte alignment (Engelmayr et al.,
2008).
An example of cardiac constructs
displaying the elasto-mechanical prop-
erties of the myocardium is given by the
incorporation of thiophene-conjugated
carbon nanotubes (T-CNTs) into poly-
caprolactone (PCL) electrospun meshes
(Wickham et al., 2014) and using
the polymer 3-hydroxybutyrate and
3-hydroxyvalerate (PHBHV). The com-
bination of PHBHV with gelatin resulted
in a 3D scaffold resembling the physico-
chemical properties, micro-topography,
and mechanics of the myocardium
(Cristallini et al., 2014).
Given the superior performance in
terms of survival and function of 3D
co-cultures including endothelial cells
(or their progenitors) and embryonic
fibroblasts in skeletal muscle engineering
(Levenberg et al., 2005), few attempts have
been taken to create complex, multicel-
lular engineered cardiac tissue constructs
(proto-tissues) in vitro to be applied on
damaged cardiac tissues.
For example, in this issue of Frontiers
in Physiology, human MSCs have been
used to provide interconnected vessel-
like structures onto gelatin scaffolds,
where pre-committed human cardiomy-
ocyte progenitor cells (CMPCs) were then
seeded (Pagliari et al., 2014).
Alternatively, a heterogeneous neona-
tal cardiac cell preparation was seeded
onto fibrin gels until endothelial cells grew
Frontiers in Physiology | Striated Muscle Physiology September 2014 | Volume 5 | Article 365 | 2
Di Felice et al. Cardiac tissue engineering: a reflection
and an adequate contractile activity was
registered (Tao et al., 2014).
Scaffolds may represent a very useful
device to deliver cardiac stem cells to the
ischemic or damaged heart. Besides the
dream of generating personalized proto-
tissues with finely controlled size and
shape to match the particular need of the
patient, the formulations proposed are far
from reproducing the complexity of the
cardiac tissue.
The use of medical devices may help
researchers to reduce the number of
implanted cells and to drive their differ-
entiation through the use of embedded
molecules or growth factors. And while the
physico-chemical features of the scaffold
proved to be important in prompting stem
cell alignment and commitment, the role
of the immune response in cardiac tissue
engineering deserves more attention.
Although promising in terms of tech-
nology advancement, the extent to which
these studies address the hierarchical orga-
nization of themyocardium is still far from
being relevant. Cardiac tissue engineer-
ing holds the promise to revolutionize the
future of heart disease treatment and the
use of scaffolds may provide valuable 3D
cues for stem cells to grow, differentiate,
and distribute into an organized tissue.
CONCLUDING REMARKS
The common limitation of the studies so
far proposed in cardiac tissue engineer-
ing remains the lack of a credible signa-
ture of complete cell maturation toward
the cardiomyocyte phenotype. Most of the
investigations showcased the expression of
proteins typical of the cardiac tissue, and
a spatial distribution or alignment of the
cells inside the scaffolds. Some research
groups were able to show a striation typi-
cal of myofibrils (Engelmayr et al., 2008),
others the massive expression of car-
diac troponins, formation of intercalated
disks, and functional gap junctions (Di
Felice et al., 2013; Cristallini et al., 2014).
Unfortunately, the extent of differentiation
shown is very far from the actual matura-
tion required to rebuild the cardiac tissue
complexity. Reproducing such complexity
would require the formation of blood ves-
sels, the connection of nerve terminations,
the participation of cells from the immune
system, fibroblasts, enterochromaffin cells,
cardiomyocytes of the conduction system.
While waiting for bio-instructive scaf-
folds displaying a modular distribution
of differentiative cues, the possibility to
combine different cell subsets with dis-
tinct potential with 3D scaffolds reproduc-
ing the hierarchical structural complexity
of the native tissue represents a valu-
able approach to generate complex cardiac
constructs to treat cardiopathic patients.
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